Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
暂无分享,去创建一个
Volker Brinkmann | Pascale Burtin | G. Francis | V. Brinkmann | R. Schmouder | A. Billich | Gordon Francis | Robert Schmouder | Peter Heining | Thomas Baumruker | Andreas Billich | P. Heining | T. Baumruker | Shreeram Aradhye | P. Burtin | S. Aradhye
[1] Y. Kurachi. G protein regulation of cardiac muscarinic potassium channel. , 1995, The American journal of physiology.
[2] V. Appay,et al. Phenotype and function of human T lymphocyte subsets: Consensus and issues , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[3] L. Kappos,et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis , 2008, Neurology.
[4] V. Brinkmann,et al. The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein‐Gated Potassium Channel IKACh , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[5] F. Sallusto,et al. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. , 2000, Science.
[6] R. Proia,et al. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. , 2003, Blood.
[7] L. Munari,et al. Interferon in relapsing-remitting multiple sclerosis. , 2001, The Cochrane database of systematic reviews.
[8] S. Traynelis,et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. , 2003, Molecular pharmacology.
[9] D S Goodin,et al. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines , 2001 .
[10] S. Karlik,et al. VEGF and angiogenesis in acute and chronic MOG(35–55) peptide induced EAE , 2009, Journal of Neuroimmunology.
[11] Massimo Filippi,et al. European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis , 2001, Annals of neurology.
[12] W. Weimar,et al. FTY720, A Novel Immunomodulator: Efficacy and Safety Results from the First Phase 2A Study in de novo Renal Transplantation , 2005, Transplantation.
[13] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[14] T. Michel,et al. VEGF induces S1P1 receptors in endothelial cells: Implications for cross-talk between sphingolipid and growth factor receptors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] D. Verzijl,et al. Sphingosine 1‐phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions , 2010, Glia.
[16] N. Rouach,et al. S1P inhibits gap junctions in astrocytes: involvement of Gi and Rho GTPase/ROCK , 2006, The European journal of neuroscience.
[17] Chi‐Huey Wong,et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses , 2005, Nature Immunology.
[18] M. Hallett,et al. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology , 2008 .
[19] Alexander Schwarz,et al. CRITICAL VASOSPASM DURING FINGOLIMOD (FTY720) TREATMENT IN A PATIENT WITH MULTIPLE SCLEROSIS , 2010, Neurology.
[20] T. Michel,et al. Sphingosine-1-phosphate and modulation of vascular tone. , 2009, Cardiovascular research.
[21] T. Junt,et al. CC Chemokine Receptor 7–dependent and –independent Pathways for Lymphocyte Homing , 2001, The Journal of experimental medicine.
[22] J. Chun,et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing–remitting experimental autoimmune encephalitis in SJL mice , 2004, Journal of Neuroimmunology.
[23] Cihan Çetin,et al. Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. , 2009, Nature chemical biology.
[24] J. Cyster,et al. S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. , 2008, Immunity.
[25] K. Johnson. An Update. , 1984, Journal of food protection.
[26] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[27] R. Bucki,et al. Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis , 2010, Neuroscience Letters.
[28] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[29] J. Kovarik,et al. A Mechanistic Study to Assess Whether Isoproterenol Can Reverse the Negative Chronotropic Effect of Fingolimod , 2008, Journal of clinical pharmacology.
[30] V. Brinkmann. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system , 2009, British journal of pharmacology.
[31] D. Lominadze,et al. Balance of S1P1 and S1P2 signaling regulates peripheral microvascular permeability in rat cremaster muscle vasculature. , 2009, American journal of physiology. Heart and circulatory physiology.
[32] H. Weiner,et al. Novel therapeutic strategies for multiple sclerosis — a multifaceted adversary , 2008, Nature Reviews Drug Discovery.
[33] Ludwig Kappos,et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[34] J. Antel,et al. FTY720 modulates human oligodendrocyte progenitor process extension and survival , 2008, Annals of neurology.
[35] A. Khoruts,et al. Visualizing the generation of memory CD4 T cells in the whole body , 2001, Nature.
[36] D. Paty,et al. Interferon beta-1b is effective in relapsing-remitting multiple-sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial , 2011, Neurology.
[37] R. Ransohoff,et al. Recovery from EAE is associated with decreased survival of encephalitogenic T cells in the CNS of B7‐1/B7‐2‐deficient mice , 2003, European journal of immunology.
[38] J. Chun,et al. Lysophospholipid activation of G protein-coupled receptors. , 2008, Sub-cellular biochemistry.
[39] B. Becher,et al. Cellular mechanisms of IL‐17‐induced blood‐brain barrier disruption , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[40] C. A. Foster,et al. FTY720 Rescue Therapy in the Dark Agouti Rat Model of Experimental Autoimmune Encephalomyelitis: Expression of Central Nervous System Genes and Reversal of Blood‐Brain‐Barrier Damage , 2009, Brain pathology.
[41] B. Oskouian,et al. The Immune Modulator FTY720 Inhibits Sphingosine-1-phosphate Lyase Activity* , 2005, Journal of Biological Chemistry.
[42] K. Toellner,et al. Changing responsiveness to chemokines allows medullary plasmablasts to leave lymph nodes , 2001, European journal of immunology.
[43] F. Lublin,et al. Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.
[44] J. Cyster,et al. Finding a way out: lymphocyte egress from lymphoid organs , 2007, Nature Immunology.
[45] N. Gray,et al. Sphingosine 1-Phosphate ( S 1 P ) Receptor Subtypes S 1 P 1 and S 1 P 3 , Respectively , Regulate Lymphocyte Recirculation and Heart Rate * , 2004 .
[46] T. Hla,et al. Immunosuppressive and Anti-angiogenic Sphingosine 1-Phosphate Receptor-1 Agonists Induce Ubiquitinylation and Proteasomal Degradation of the Receptor* , 2007, Journal of Biological Chemistry.
[47] L. Kappos,et al. Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis , 2010, Neurology.
[48] R. Proia,et al. Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes , 2004, Journal of Pharmacology and Experimental Therapeutics.
[49] H. Kataoka,et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.
[50] J. Cyster,et al. Promotion of Lymphocyte Egress into Blood and Lymph by Distinct Sources of Sphingosine-1-Phosphate , 2007, Science.
[51] E. Francotte,et al. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. , 2005, Journal of medicinal chemistry.
[52] S. Karlik,et al. VEGF and vascular changes in chronic neuroinflammation. , 2003, Journal of autoimmunity.
[53] H. Wekerle,et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions , 2009, Nature.
[54] T. Mosmann,et al. In Vivo Priming of Cd4 T Cells That Produce Interleukin (Il)-2 but Not IL-4 or Interferon (Ifn)-γ, and Can Subsequently Differentiate into IL-4–Or IFN-γ–Secreting Cells , 2001, The Journal of experimental medicine.
[55] S. A. Parent,et al. Identification of Leu276 of the S1P1 Receptor and Phe263 of the S1P3 Receptor in Interaction with Receptor Specific Agonists by Molecular Modeling, Site-Directed Mutagenesis, and Affinity Studies , 2007, Molecular Pharmacology.
[56] Y. Miyake,et al. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. , 1995, Biochemical and biophysical research communications.
[57] Frauke Zipp,et al. Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL , 2005, Neuron.
[58] F. Patti. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence , 2010, Patient preference and adherence.
[59] M. Rausch,et al. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: Clinical implications for ultrasmall superparamagnetic iron oxide‐enhanced magnetic resonance imaging , 2004, Journal of magnetic resonance imaging : JMRI.
[60] M. Schwab,et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine‐1‐phosphate receptors , 2007, Journal of neurochemistry.
[61] H. Sasaki,et al. Update on the treatment options for multiple sclerosis , 2010, Expert review of clinical immunology.
[62] V. Brinkmann,et al. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. , 2001, Transplantation proceedings.
[63] A. Zimmermann,et al. Effects of immunosuppressant FTY720 on renal and hepatic hemodynamics in the rat , 2002, Transplantation.
[64] E. Goetzl,et al. The immunosuppressant FTY720 down‐regulates sphingosine 1‐phosphate G protein‐coupled receptors , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[65] E. Persohn,et al. Brain Penetration of the Oral Immunomodulatory Drug FTY720 and Its Phosphorylation in the Central Nervous System during Experimental Autoimmune Encephalomyelitis: Consequences for Mode of Action in Multiple Sclerosis , 2007, Journal of Pharmacology and Experimental Therapeutics.
[66] H. Wekerle,et al. Intravital 2-photon imaging of encephalitogenic effector cells during fingolimod (FTY720) treatment of experimental autoimmune encephalomyelitis , 2008 .
[67] E. Billy,et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. , 2006, Cancer research.
[68] X. Montalban,et al. Oral fingolimod (FTY720) in multiple sclerosis , 2009, Neurology.
[69] V. Brinkmann. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. , 2007, Pharmacology & therapeutics.
[70] J. Kovarik,et al. Overview of FTY720 clinical pharmacokinetics and pharmacology. , 2004, Therapeutic drug monitoring.
[71] Y. Yamori,et al. Sphingosine 1‐phosphate induces the production of glial cell line‐derived neurotrophic factor and cellular proliferation in astrocytes , 2003, Glia.
[72] N. Gray,et al. Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate* , 2004, Journal of Biological Chemistry.
[73] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.
[74] S. Spiegel,et al. Identification of Edg1 Receptor Residues That Recognize Sphingosine 1-Phosphate* , 2000, The Journal of Biological Chemistry.
[75] M. Straume,et al. Transient T cell accumulation in lymph nodes and sustained lymphopenia in mice treated with FTY720 , 2005, European journal of immunology.
[76] S. Kaufmann,et al. Requirement of secondary lymphoid tissues for the induction of primary and secondary T cell responses against Listeria monocytogenes , 2008, European journal of immunology.
[77] K. Claffey,et al. Phosphorylation and Action of the Immunomodulator FTY720 Inhibits Vascular Endothelial Cell Growth Factor-induced Vascular Permeability* , 2003, Journal of Biological Chemistry.
[78] Peter Natesan Pushparaj,et al. Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia , 2010, Neuroscience.
[79] M. Pangalos,et al. Edg8/S1P5: An Oligodendroglial Receptor with Dual Function on Process Retraction and Cell Survival , 2005, The Journal of Neuroscience.
[80] Ying Xu,et al. Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning , 2009, The Journal of experimental medicine.
[81] B. Kinzel,et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. , 2006, Blood.
[82] K. Sugahara,et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. , 1998, Journal of immunology.
[83] Masanori Nakamura,et al. Immunosuppressant FTY720 inhibits thymocyte emigration , 2000, European journal of immunology.
[84] M. Buttmann. Treating multiple sclerosis with monoclonal antibodies: a 2010 update , 2010, Expert review of neurotherapeutics.
[85] J. Chun,et al. Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes , 2003, Brain Research.
[86] Matthias Mueller,et al. Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure. , 2008, International immunology.
[87] F. Sallusto,et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.
[88] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[89] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[90] J. Cyster,et al. FTY720: Sphingosine 1‐Phosphate Receptor‐1 in the Control of Lymphocyte Egress and Endothelial Barrier Function , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[91] J. Kovarik,et al. Oral‐intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects , 2007, Biopharmaceutics & drug disposition.
[92] D. Mazurais,et al. Cell Type-specific Localization of Human Cardiac S1P Receptors , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[93] S. Schreiber,et al. The identification of myriocin-binding proteins. , 1999, Chemistry & biology.
[94] G. Rosati,et al. The prevalence of multiple sclerosis in the world: an update , 2001, Neurological Sciences.
[95] A. Lanzavecchia,et al. The duration of antigenic stimulation determines the fate of naive and effector T cells. , 1998, Immunity.
[96] K. Jakobs,et al. Activation of muscarinic K+ current in guinea‐pig atrial myocytes by sphingosine‐1‐phosphate. , 1995, The Journal of physiology.
[97] J. Kovarik,et al. The ability of atropine to prevent and reverse the negative chronotropic effect of fingolimod in healthy subjects. , 2008, British journal of clinical pharmacology.
[98] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[99] R. Proia,et al. Sphingosine kinase 1/S1P receptor signaling axis controls glial proliferation in mice with Sandhoff disease. , 2008, Human molecular genetics.
[100] T. Hla,et al. Lysophospholipid receptors in vertebrate development, physiology, and pathology Published, JLR Papers in Press, December 8, 2008. , 2009, Journal of Lipid Research.
[101] R. Ransohoff,et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. , 2010, Immunity.
[102] M. Koyama,et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. , 2005, Cellular & molecular immunology.
[103] Michael D. Davis,et al. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.
[104] R. Bronson,et al. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. , 2003, The Journal of clinical investigation.
[105] S. Yuan,et al. Regulation of Endothelial Barrier Function , 2011 .
[106] T. Fujita,et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720 , 1995 .
[107] C. A. Foster,et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis , 2007, Brain Research Bulletin.
[108] R. Proia,et al. Expression of the Sphingosine 1-Phosphate Receptor, S1P1, on T-cells Controls Thymic Emigration* , 2004, Journal of Biological Chemistry.
[109] Nathalie Arbour,et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation , 2007, Nature Medicine.
[110] R. Proia,et al. Essential Role for Sphingosine Kinases in Neural and Vascular Development , 2005, Molecular and Cellular Biology.
[111] X. Montalban,et al. Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results , 2010, Multiple sclerosis.
[112] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[113] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[114] S. Spiegel,et al. Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling , 2005, Journal of Cell Science.
[115] R. Zinkernagel,et al. FTY720 Immunosuppression Impairs Effector T Cell Peripheral Homing Without Affecting Induction, Expansion, and Memory1 , 2000, The Journal of Immunology.
[116] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[117] V. Brinkmann,et al. FTY720 alters lymphocyte homing and protects allografts without inducing general immunosuppression. , 2001, Transplantation proceedings.
[118] L. Kappos,et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS , 2007, Neurology.
[119] A. Melendez,et al. Recent trials for FTY720 (fingolimod): a new generation of immunomodulators structurally similar to sphingosine. , 2008, Reviews on recent clinical trials.
[120] H. Schluesener,et al. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves , 2008, Experimental Neurology.
[121] N. Putzki,et al. Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland , 2010, European Neurology.
[122] L. Lefrançois,et al. Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue , 2001, Science.
[123] Y. Yanagawa,et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. , 1996, Transplantation proceedings.
[124] T. Phan,et al. Cortical sinus probing, S1P1-dependent entry and flow-based capture of egressing T cells , 2008, Nature Immunology.
[125] M. Moskowitz,et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase , 1995, Nature.
[126] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.
[127] S. Enosawa,et al. A new immunosuppressant, FTY720, induces bcl‐2‐associated apoptotic cell death in human lymphocytes , 1996, Immunology.
[128] S. Payne,et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. , 2007, Blood.
[129] S. Mulgaonkar,et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study , 2003, Transplantation.
[130] T. Ohmori,et al. Essential Roles of Sphingosine 1‐Phosphate/S1P1 Receptor Axis in the Migration of Neural Stem Cells Toward a Site of Spinal Cord Injury , 2007, Stem cells.
[131] A. Lanzavecchia,et al. Migration and Function of Antigen-Primed Nonpolarized T Lymphocytes in Vivo , 2001, The Journal of experimental medicine.
[132] Antonio Lanzavecchia,et al. Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.
[133] J. Geddes,et al. Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS , 2010, Neurology.
[134] L. Feng,et al. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. , 2000, Trends in pharmacological sciences.
[135] Caiying Guo,et al. Cell-surface residence of sphingosine 1-phosphate receptor 1 on lymphocytes determines lymphocyte egress kinetics , 2010, The Journal of experimental medicine.
[136] R. Ravid,et al. Expression of CCR7 in multiple sclerosis: Implications for CNS immunity , 2004, Annals of neurology.
[137] H. Rabb,et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. , 2004, American journal of respiratory and critical care medicine.
[138] V. Brinkmann,et al. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. , 2002, Current opinion in immunology.
[139] S. Ludwin,et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. , 2010, The American journal of pathology.
[140] K. Budde,et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. , 2002, Journal of the American Society of Nephrology : JASN.
[141] H. Schluesener,et al. FTY720 attenuates lesional interleukin‐17+ cell accumulation in rat experimental autoimmune neuritis , 2009, Neuropathology and applied neurobiology.
[142] L. Steinman. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab , 2005, Nature Reviews Drug Discovery.
[143] R. Proia,et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1 , 2004, Nature.
[144] Joe G. N. Garcia,et al. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. , 2005, Cellular signalling.
[145] H. Amemiya,et al. Amelioration of Experimental Autoimmune Encephalomyelitis in Lewis Rats by FTY720 Treatment , 2003, Journal of Pharmacology and Experimental Therapeutics.
[146] P. Gonzalez-Cabrera,et al. Tipping the gatekeeper: S1P regulation of endothelial barrier function. , 2007, Trends in immunology.
[147] A. Prescher,et al. Protective Effects of Early CD4+ T Cell Reduction in Hepatic Ischemia/Reperfusion Injury , 2010, Journal of Gastrointestinal Surgery.
[148] S. Sidney,et al. The 5-year direct medical cost of neonatal and childhood stroke in a population-based cohort , 2010, Neurology.
[149] H. Rosen,et al. Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.
[150] Ian Parker,et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo , 2006, Nature chemical biology.
[151] H. Rosen,et al. Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm. , 2003, Current opinion in chemical biology.
[152] T. Fujita,et al. Design, Synthesis, and Structure-Activity Relationships of 2- Substituted-2-amino-1,3-propanediols: Discovery of a Novel Immunosuppressant, FTY720. , 1995 .
[153] E. Pamer,et al. Priming of Memory But Not Effector CD8 T Cells by a Killed Bacterial Vaccine , 2001, Science.
[154] Mechanistic insights , 2022 .
[155] S. Enosawa,et al. Induction of selective cell death targeting on mature T-lymphocytes in rats by a novel immunosuppressant, FTY720. , 1996, Immunopharmacology.
[156] C. Polman,et al. In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology , 2005, Journal of Neuroimmunology.